Five things for pharma marketers to know: Friday, December 16, 2016

Share this content:

1. Allergan will pay $38 million to settle allegations that its Forest Laboratories and Forest Pharmaceuticals subsidiaries did not appropriately control payments made to physicians for speakers bureaus. The speaking events were for hypertension drug Bystolic, Alzheimer's disease treatment Namenda, and fibromyalgia drug Savella. (WSJ)

2. Mylan launched the generic version of its EpiPen allergy treatment. The generic is 50% cheaper than the branded product and was developed in response to criticism over price hikes of the EpiPen. (Reuters)

3. Mylan is also one of six drugmakers accused by 20 state attorneys general of price-fixing. The civil complaint alleges that the companies conspired to artificially inflate prices on an antibiotic and a diabetes drug. (NYT)

4. Gilead Sciences must pay $2.54 billion to Merck for violating a patent that was used to develop its blockbuster hepatitis-C drugs Harvoni and Sovaldi. A federal jury deliberated for less than two hours. (Bloomberg)

5. The Justice Department is investigating Omnicom Group over concerns about contract pricing manipulation. The firm said two of its agencies received subpoenas this week. (WSJ)

Share this content:
Scroll down to see the next article